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Abstract
The ultimate goal to provide a cure for all patients suffering from type-1-diabetes has 
remained out of the patients reach despite major advances in technologies. There has 
however, for a number of decades been a concerted effort to use various forms of por-
cine β-cells as a replacement transplant alternative to cadaveric human donors.  This has 
seen major advances in the last decade with significant development of multi-transgenic 
donor pigs that now can potentially be used for xenotransplantation. This has been 
achieved with cellular transplants leading the way using porcine islet cell transplants 
as a form of β cell replacement in pre-clinical studies to treat diabetic non-human pri-
mates in various guises. These uniquely modified islet cells have the potential to offer 
an unlimited source of insulin-producing cells once we have solved all of the issues 
required to prevent loss of the xenotransplant. This chapter provides an in depth over-
view as to how the most recent advances have been achieved in regards to the genetic 
modification of donor pigs to provide protection from hyperacute rejection, instant 
blood mediated inflammatory reaction, xenoantibody and cellular responses to provide 
long-term functional islet cell xenotransplants to be able to move islet cell xenotrans-
plantation to the clinic.
Keywords: clustered regularly interspaced short palindromic repeats, diabetes mellitus, 
graft rejection, immunosuppression, islets of langerhans, primates, swine, 
transplantation, hyperacute rejection, instant blood-mediated inflammatory reaction, 
islet cell transplantation, neonatal islet cell clusters, thrombosis, Type-1-diabetes, 
transcription activator-like effector nucleases, xenotransplantation, zinc finger nucleases
1. Introduction
The major landmark in the development of a treatment for type-1-diabetes (T1D) occurred 
almost a century ago, with conventional treatment still utilising exogenous insulin therapy. 
© 2017 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
Clearly for the majority of this time the main stay for its use was that of porcine insulin until 
it was usurped by recombinant human insulin in the early 1980s [1]. Despite the develop-
ment of these newer insulin’s and their modified treatment regimens still used to this day, 
insulin’s role only remains in the prevention of elevations of blood sugar levels which ulti-
mately give rise to ketoacidosis and ultimately death, where it is not adequately controlled 
[2]. Even with the advent of the insulin pump (IP) and integrated control with a Glucose 
Management System (GMS) the fact remains that the life-saving benefits of exogenous insu-
lin therapy are still inadequate to prevent the serious long-term secondary complications of 
T1D. Sadly, patients with T1D still suffer significantly from cardiac disease, nephropathy, 
retinopathy and micro vascular disease. Even with the use of insulin pumps, it still has not 
reduced the severe hypoglycemic episodes resulting in coma and even death of these patients 
due to the significant lack of biofeedback and blood sugar re-balancing by glucagon secretion 
as produced by islet cells [3, 4].
The current transplant treatments being offered to patients suffering from T1D, both whole 
organ pancreas and pancreatic islet cell allotransplantation remain the Gold standard in 
treatment but are only available to treat small numbers, more or less just subsets of patients 
with T1D. In the case of simultaneous pancreas and kidney (SPK) transplantation where 
the whole pancreas is transplanted in combination with the kidney to treat patients with 
T1D and renal failure these patients do incredibly well, but this transplant is a major surgi-
cal procedure that is not an option for all patients suffering from T1D [5, 6]. Likewise islet 
cell transplantation remains an option only for the small subset of patients suffering severe 
hypoglycemic unawareness [7, 8]. These patients have seen great benefits from their trans-
plants such as protection from hypoglycemia and from the progression of the severe sec-
ondary complications. Despite the benefits pancreas and islet allotransplantation provide, 
we remain unable to offer these treatments universally to all patients with T1D due to the 
significant shortage of donor organs and the need for continuous immunosuppression to 
prevent graft rejection [9, 10].
The major reason we may never be able to offer widespread application of such trans-
plants is the sad and unfulfilled ability to provide what is an extremely valuable resource 
in that of human organ donor supply, where a gap remains unlikely ever to be filled 
with a disproportionate gap in the supply as compared to the demand for transplants. 
To be able to offer an alternative source of tissue for clinical transplantation we must be 
able to produce cells that are demonstrated to be safe and effective from a reproducible 
alternative source of β-cell replacement tissues [11]. Decades of concerted effort in the 
xenotransplantation field has seen the emergence of porcine islets as the most plausible 
source of tissues to provide a safe, effective, reliable and renewable source of islet cell 
tissues [12]. However, in order for xeno-islet-transplantation to move to clinical therapy 
we must clearly provide a safe and stable porcine donor source that avoids the many 
existing barriers of xenotransplantation, including the necessity for a suitable and effec-
tive immunosuppressive regimen [13]. To be able to do this, those of us in the xenotrans-
plantation field have concentrated on utilizing the pig as the donor source due to it being 
an easily housed and bred animal that has been farmed for centuries. It is also of a large 
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enough size that organs from pigs can quite readily size match humans for transplanta-
tion. Additionally, for such a large animal they are also rather unique, having a relatively 
short gestational cycle being less than four months (3 months 3 weeks 3 days) and they 
produce large litters (generally 10 but can have up to 20 in a single litter). This places 
them in a rather fortuitous position for us to be able to utilize them as a reproducible tis-
sue source for generation of donors for tissues and cells, following appropriate genetic 
manipulation. Genetic manipulation has been necessary in order to be able to transplant 
pig tissues across the xenogeneic barriers into humans and this has taken multiple trans-
genes to achieve [11, 14].
Xenotransplantation leads all other technologies in the race to provide a viable source of 
transplantable tissues to treat T1D due to the incredible advances in technologies provid-
ing the ability to manipulate the donor tissues or cells prior to transplantation. Over the last 
two decades we have seen incredible advances and changes in the technologies available for 
such, even since the first genetically manipulated transgenic pigs were produced express-
ing the human complement regulator CD59 [15], we have seen more dramatic advances due 
to the rapid adoption of extremely cutting edge technologies which are further discussed 
below. This is even reflected in the more traditional cloning technologies where zinc finger 
nucleases (ZFNs) [16, 17] have been used to develop a number of new pig lines. But by far the 
most effective and potentially further productive multiple transgenic combinations has been 
the adoption of targeted gene knockouts using transcription activator-like effector nucleases 
(TALENs) where there have been amazing advances in the production of pigs with multiple 
genetic knockouts [18]. The more recent advances have slingshot the production of transgenic 
pigs forward many years by the use of type II clustered regularly interspaced short palin-
dromic repeats (CRISPR)/Cas9 system [19–21]. These various strategies of genetic modifica-
tion have ‘humanized’ the transgenic pig to be more readily usable in the clinical setting. 
Most notably, these approaches have aimed at either antigen reduction or human transgene 
expression [22].
This chapter provides an in depth overview as to how the most recent advances have been 
made in regards to the genetic modification of donor pigs to provide protection from hyper-
acute rejection, IBMIR, Xeno antibody and cellular responses to provide long-term functional 
islet cell xenotransplants to be able to move islet cell xenotransplantation to the clinic.
2. Overcoming the Islet‐specific barriers inhibiting islet 
xenotransplantation
Islet cell xenotransplantation has been plagued by not only xenotransplant barriers but 
also islet specific barriers, which have inhibited its success until they have recently been 
 overcome. The most significant barrier in xenotransplantation has been seen at the time 
of first point of contact with the recipient’s blood stream and thus the cellular and anti-
body targeting cofactors. Primary graft loss can occur almost immediately following the first 
direct recipient blood contact with the graft. This is due, principally, to hyperacute rejection 
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(HAR). HAR occurs when the xenoreactive natural pre-formed antibodies to the oligosac-
charide galactose α1-3 galactose (αGal) of the recipient recognize the xenoantigen on the 
graft endothelium, and the resulting complement-mediated immune response leads to the 
triggering of the cascade of humoral and cellular events. These preexisting antigens on the 
cell surface of the donor tissue are rapidly recognized by the recipient’s antibodies after 
revascularization which initiates the complement coagulation cascade, leading to throm-
bosis and edema and also the triggering of cellular inflammation that destroys the graft as 
quickly as within minutes to hours.
More readily observed in whole vascularized organs where HAR is characterized by immedi-
ate vascular engorgement and discoloration of the organ as can be seen in Figure 1 of a kidney 
transplant one-hour post-transplantation whilst undergoing HAR.
Islets do not have large blood vessels or a significant vascular endothelium for this to occur 
in the same way. However, islets are infused into the vasculature of the liver usually via the 
portal vein. Following their transplantation into the liver’s sinusoids, they trigger an almost 
immediate and profound micro and macro-vascular thrombotic change within the liver. This 
ultimately leads to larger vessel thrombosis and potentially thrombosis of the liver that they 
have been transplanted into [23].
Also at the time of transplantation islet cells are exposed to other barriers such as islet specific 
inflammation (instant blood mediated inflammatory reaction) referred to as IBMIR [24]. IBMIR 
was first demonstrated by William Bennet a PhD student in the Swedish group of Korsgren 
and Groth where he exposed human islets to freshly collected human ABO-compatible non-
anticoagulated blood which he placed together into surface coated-heparinized polyvinyl 
chloride tubing loops to observe the resultant reactions and then subsequently also performed 
intraportal transplantation of porcine islets into pigs to observe and report on the advent of 
IBMIR [24].
Others have subsequently explored this process in depth using both human and xeno-islets. 
What they discovered was that allo-islets coalesced and ended up embedded in clots, where 
Figure 1. (A) Hyperacute rejection of a kidney graft 1 h post revascularisation. (B) Note the extremely engorged 
appearance of the graft with vascular thrombosis, engorgement and edema of the pulp of the graft.
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they were infiltrated specifically with leukocytes and their cellular morphology was dis-
rupted. Xeno-islets tend to also be infiltrated with neutrophils and the process occurring in 
a more aggressive and destructive manner [25, 26]. The macro-loop system setup provides 
a useful tool to explore the mechanisms that occur in IBMIR in both allo and xeno islet 
transplantation. The setup of the loop system can be seen in Figure 2 where porcine islets 
are mixed with 7 ml of freshly collected human ABO compatible blood and incubated for 
an hour.
Fortuitously this process can be abrogated with the addition of anticoagulants such as hepa-
rin, which are added to the islet milieu in combination with a soluble complement receptor, 
completely preventing or delaying this process from occurring. More specifically it can pre-
vent the initial triggering of the inflammation and as such reduce both initial islet loss and 
subsequent specific immune responses [25, 26]. However, in the Xenotransplantation setting 
it appears that the same protection may not be offered unless islets are specifically developed 
to avoid the IBMIR process.
In addition to these immune activated processes, pancreata and islets are also extremely 
affected by hypoxia that occurs with the organ donation process and removal of the organ 
from its blood supply. More significantly the loss of islet cell vascularization and the deprava-
tion of oxygen to the islets during the islet isolation process cause significant damage and loss 
of the islets [27].
We therefore have a number of unique possibilities, as we are able to develop transgenic 
pigs as donors where we can address these various problems and prevent them from occur-
ring. With the genetic engineering of porcine donors we can modify them in such a way that 
they are more compatible with the human recipients they will be transplanted into. Multiple 
genetic manipulations have already proven useful specifically in relation to hyperacute rejec-
tion, IBMIR, hypoxia, innate immune responses and even T cells with the potential of even 
further advancement in the near future [28].
Figure 2. (A) An orbital mixer incubator with the PVC tubing loops containing porcine islets mixed with freshly collected 
non-anticoagulated human ABO-compatible blood. (B) The resultant clot after one hour of incubation of wild type 
porcine islets mixed with freshly collected non-anticoagulated human ABO-compatible blood.
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2.1. Overcoming hyperacute rejection by genetic modification
The most impacting of the barriers, HAR, caused by the existence of the pre-formed anti-
bodies to αGal prevent direct xenotransplantation as they are expressed at high levels on 
pig cells and in particular on islet cells, but the rate differs depending on the age of the pigs, 
seen at their highest levels on neonatal islet cells [29, 30]. In an eloquent study Rayat et al. 
examined αGal expression on various porcine islet cell preparations and correlated this 
with the proportion of cytokeratin 7 (CK7)-positive ductal cells. In vitro and in vivo expres-
sion of αGal and CK7 was significantly (p < 0.05) higher in less mature neonatal islet cells 
compared with matured neonatal islet and adult porcine islet cells, while the reverse was 
observed in the proportion of beta cells [31]. These pre-formed antibodies to the oligosac-
charide galactose α1-3 galactose are not on human tissue and thus HAR does not occur in 
the allo setting [32].
Attempts to prevent HAR, for example by depletion of anti-pig Abs in recipients, were 
not very successful and it was not until genetic modification of donor pigs that any form 
of protection was provided. Numerous studies have subsequently utilized an array of 
genetic modifications in the genetically modified donor pigs for protection. But by far the 
most dramatic of impacts was that seen when the first genetic modification occurred with 
the deletion of the xenoantigen αGal known as the Gal Transferase Knockout (GTKO) 
[33–35], which still remains the pig of choice as the genetic background for application of 
further genetic modifications. There has been quite profound data showing that follow-
ing the genetic manipulation of pigs to have transplantation of neonatal porcine GTKO 
islets into diabetic rhesus macaques, the neonatal porcine GTKO islets had significantly 
decreased susceptibility of the xenografts to innate immunity mediated by complement 
and preformed xenoantibody, and increased survival and function when compared to 
wild type islets [36]. We also saw the same abrogative effects in baboons transplanted 
with porcine neonatal islet cell clusters (NICC) from pigs with GTKO background when 
compared to wild type NICC [37]. The profound effects of transplanting wild type NICC 
into the baboon liver produced an almost immediate production of micro-thrombi sur-
rounding the αGal-positive wild type NICC. This clot contained fibrin, RBC, and leu-
kocytic infiltrate from as early as 1-hour post-transplant. Even using a combination of 
anticoagulation consisting of heparin and recombinant human  antithrombin NICC’s 
underwent HAR. NICC were surrounded by large numbers of platelets, monocytes 
and neutrophils and areas staining positively for complement C3c in surrounding clot. 
Neutrophils were seen infiltrating NICC that stained positive for IgG deposition, leading 
to early destruction [37]. As can be seen in Figure 3A the Wild type NICC were trapped 
in clots, whereas can be seen in Figure 3B the GTKO background NICC were not throm-
bosed at all at any stage post transplant being able to survive long-term for more than a 
year post transplant.
In a very short space of time technology has leapt forward and we have established a new 
era in molecular biology with the advent of novel and extremely cutting edge technologies, 
which make great changes to the way we genetically modify pigs. The most amazing leap 
forward came with a new tool based on a bacterial CRISPR and CRISPR-associated (Cas), in 
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particular the associated protein-9 nuclease (Cas9) from Streptococcus pyogenes which has led 
to a  revolution in technology, causing considerable excitement in the entire science world let 
alone in xenotransplantation. In particular the genes have great potential to be exploited in 
the system for RNA-programmable genome editing [38]. Now a number of groups have been 
able to use the CRISPR/Cas9 system to efficiently perform biallelic knockout of the α-1,3-
galactosyltransferase gene in porcine blastocysts derived from the somatic cell nuclear trans-
fer of αGal epitope-negative cells which also lacked the αGal epitope on their surface [39].
There have also been a number of other quite recent publications in which it has been shown that 
researchers have targeted various combinations to delete α(1,3)galactosyl transferase (GGTA1), 
the gene for the enzyme cytidine monophospho-N-acetylneuraminic acid hydroxylase (CMAH) 
resulting in the generation of pigs that do not express NeuGc [20]. We have also seen the use 
of the slightly older but still cutting edge technology that is still very effective, TALENs which 
has been designed to target exon 6 of porcine GGTA1 gene resulting in the production of 
GGTA1-null miniature pigs [40, 41]. Miyagawa and colleagues were the first to generate the α1,3 
galactosyltransferase and cytidine monophospho-N-acetylneuraminic acid hydroxylase gene 
double-knockout pigs using this system [40]. ZFNs and somatic cell nuclear transfer have also 
been used for the generation of GGTA1 biallelic (double) knockout pigs [17, 42].
Quite clearly the multitude of very new and extremely effective technologies have provided 
an array of avenues to establish a clear platform from which we can progress additional 
genetic manipulations required to move xeno islets to the clinic.
2.2. Overcoming IBMIR by genetic modification
IBMIR is also a well-known mechanism effecting islets and islet like cells, which can occur 
almost immediately or even up to hours after the islet infusion in the allo, auto and xeno-
graft setting [43, 44]. Islets specifically undergo targeted innate thrombotic and  inflammatory 
Figure 3. (A) A photomicrograph from a histology slide of a biopsy of a baboon liver transplanted with wild type 
NICC, note the two NICCs contained in a large clot consisting of RCC, platelets, fibrin and infiltrating cells that almost 
obstruct the entire venule it is sitting in. Section is at 100× magnification and stain is H&E. (B) A photomicrograph from 
a histology slide of a biopsy from a baboon liver transplanted with NICC from GTKO background neonatal pig, the islet 
is intact and well revascularized with minimal infiltration at 1 week post transplant, note the open portal venule with no 
sign of micro or macrovascular thrombosis. Section is at 200× magnification and stain is MSB.
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responses, which, like HAR results in coagulation, complement activation, infiltration of 
immune cells and platelet adhesion [45]. Certainly one of the major players appears to be 
complement activation, especially via the alternative pathway, which has been shown to 
greatly contribute to the triggering of IBMIR in the non-human primate (NHP) islet setting 
[13]. Specifically the triggering of IBMIR revolves around the release of inflammatory media-
tors including IL-8, MCP-1 and macrophage migration inhibitory factor which is very simi-
lar to what occurs in HAR with the triggering of thrombin then promoting the activation of 
monocytes, neutrophils and platelets that aggregate at the point of contact with the graft. 
It appears the major trigger for IBMIR therefore is tissue factor, which is expressed on the 
surface of islets and also the fragments of acinar tissue, which surround or are sometimes 
attached to the islet [43, 46, 47].
More complex than originally thought, it also appears that there is a synergistic influence 
between the coagulation cascade and platelets which are thought to exacerbate IBMIR and 
as such continues the destructive cycle without direct triggering. Experimental complement 
activation can be controlled by cobra venom factor, coagulation by heparin or low molecular 
weight dextran, and platelet activation by anti-platelet agents such as Plavix [13]. This is use-
ful as proof of principal in the experimental setting where these drugs and agents have been 
used, however, it is best that they are not used clinically, so alternative drugs and agents spe-
cifically targeting complement such as Compstatin, human factor H (HFH) and intravenous 
immunoglobulin (IVIG) are under investigation [13]. Quite clearly, as pointed out more than 
a decade ago, if we are to make inroads into preventing IBMIR of islets or islet like tissues we 
must block tissue factor or inhibit its expression to prevent the thrombotic response in vitro 
[44, 45].
Fortunately, like the problems of HAR, this barrier has been overcome by the clever genetic 
modification of the donor pig to avoid αGal but also express human complement regula-
tors such as CD46/55/59 [37]. Promising results have been achieved with porcine islets from 
hCD46-expressing pigs, which were transplanted into diabetic cynomolgus monkeys, nor-
moglycemia was achieved in four of five monkeys with up to 3 months follow-up [48]. By 
far the most impressive results to date were achieved when porcine islets from αGal-defi-
cient pigs, protecting against the pre-existing xeno antibodies, and also transgenic for the 
human complement regulators CD55 and CD59 were transplanted into the immunologically 
taxing baboon model. The baboons received NICC and were treated with a clinically relevant 
immunosuppressive protocol. The islets were less susceptible to humoral injury, induced sig-
nificantly less complement activation and thrombin generation limiting antibody-mediated 
rejection compared to wild type thus proving that xeno islets can be protected from both HAR 
and IBMIR in the xenotransplant setting [23].
Following the rapid uptake of the most cutting-edge technologies by the xenotransplant 
community we have seen dramatic advances in xenotransplantation with the CRISPR/Cas9-
directed mutation and human transgene delivery system that have been used to geneti-
cally modify and develop specific pigs to prevent HAR. CRISPR/Cas9 was used to delete 
the GGTA1, cytidine monophosphate-N-acetylneuraminic acid hydroxylase (CMAH) and 
Beta-1,4-N-Acetyl-Galactosaminyl Transferase2 (B4GALNT2) genes. As a very targeted use 
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of the CRISPR/Cas9 system this approach provided a significant xenoantigen reduction with 
the abolition of the porcine carbohydrate profiles and as such effectively prevented antibody-
mediated complement dependent cytotoxicity from occurring [22].
These genetic modifications to protect against HAR and IBMIR have been mitigated by genet-
ically disrupting the α1,3-galactosyltransferase gene and other targeted approaches to reduce 
xenogenicity as shown above by targeting the many various transgenes such as; GLA, HT, 
hGnT-III, GT-KO, CMAH, (Neu5Gc)-KO, class I MHC-KO, iGb3s-KO, β4GalNT2-KO [11, 13, 
17, 22, 23, 37, 40–42]. Clearly remarkable these have made massive inroads in the direction 
that we need to travel to be able to move islet xenotransplantation to the clinic.
2.3. Overcoming hypoxia and inflammation by genetic modification
Ultimately the overt processes of organ donation and the islet cell isolation strip and denude 
the islet cells of their vasculature and deprive the islets of the oxygen and nutrients they 
require to sustain them. Ultimately this causes irreversible damage to the islets resulting in 
graft loss. Obviously the main cause of this is from hypoxia and as such is contributed to 
by hypoxia inducible factor (HIF)-1α and activation of its target genes that end up causing 
impaired islet function, apoptosis and eventually cell death [49–51]. One of the fundamental 
ways to potentially improve outcomes is to increase the oxygen delivery to the cells during 
the organ retrieval process. This has been undertaken by the use of various experimental 
devices such as the use of the two layer method [52, 53] and also by the experimental use of 
persuflation [11]. The two-layer method (TLM) utilizes a perfluorochemical (PFC) and UW 
solution to store the pancreas during shipping. The benefits of the use of the PFC are theoreti-
cally because it is a biologically inert liquid that acts as an oxygen-supplying media. A pan-
creas preserved using the TLM is oxygenated through the PFC and substrates are supplied by 
the UW solution. Reportedly this allows the pancreas to be better preserved using the TLM to 
generate adenosine triphosphate during storage, prolonging the preservation time [11].
Numerous attempts have been undertaken to improve the supply of oxygen to islets includ-
ing in situ oxygen generation and improved revascularization of the graft and the islets them-
selves [54] along with possible systemic treatments of the islets during culture and transplant 
using already clinically approved agents such as desferrioxamine (DFO) [55]. There have 
been a few ways developed to improve hypoxia by the modification of the xenotransplant 
utilizing genetic modification of the donor pig to date.
The most specific targets investigated have been using the transgenic expression of the 
human A20 gene in cloned pigs. The zinc finger protein A20 is an important negative 
regulator of inflammation; polymorphisms in the corresponding gene, TNFAIP3, have 
been reported to be associated with numerous inflammatory diseases. The A20 gene is 
thought to provide  protection against apoptotic and inflammatory stimuli but studies 
to date have been restricted to heart, skeletal muscle and porcine aortic endothelial cells 
(PAECs) of transgenic animals. Cultivated hA20-transgenic PAECs were protected against 
TNF-α-mediated apoptosis, and partially protected against CD95 (Fas)L-mediated cell 
death and the pig cardiomyocytes were partially protected in ischemia/reperfusion stud-
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ies. This study demonstrated that human A20 expression on pig cells could be a promis-
ing molecule for protection against hypoxia in xenotransplantation studies and it may 
also play a role in protection against the innate immune response [56]. More specifically 
we can produce pigs with transgenic expression of human heme oxygenase-1 (hHO-1), 
an inducible protein capable of cytoprotection by scavenging reactive oxygen species and 
preventing apoptosis caused by cellular stress during inflammatory processes [57]. The 
Korean group of Curie Ahn developed a hHO-1 expressing pig and analyzed the expres-
sion and function of the transgene. Human HO-1 was expressed in tissues, including the 
heart, kidney, lung, pancreas, spleen and skin. Fibroblasts derived from the hHO-1 trans-
genic pigs were significantly resistant to both hydrogen peroxide damage and hTNF-α 
and cycloheximide-mediated apoptosis when compared with wild-type pig fibroblasts. 
Furthermore, induction of RANTES in response to hTNF-α or LPS was significantly 
decreased in fibroblasts obtained from the hHO-1 transgenic pigs. These findings suggest 
that transgenic expression of hHO-1 can protect xenografts when exposed to oxidative 
stresses, especially from ischemia/reperfusion injury, and/or acute rejection mediated by 
cytokines [57].
More recently, the CRISPR/Cas9 system was used to yield human cells devoid of man-
ganese superoxide dismutase (MnSOD). SOD2-null cells displayed perturbations in their 
mitochondrial ultrastructure and preferred glycolysis as opposed to oxidative phosphoryla-
tion to generate ATP [58]. We have also seen the development of various pigs that have the 
addition of a potential anti-inflammatory genes such as human CD39 (hCD39), the major 
vascular nucleoside triphosphate diphosphohydrolase (NTPDase), converts ATP and ADP 
to AMP, which is further degraded to the antithrombotic and anti-inflammatory media-
tor adenosine. Deletion of CD39 renders mice exquisitely sensitive to vascular injury, and 
CD39-null cardiac xenografts show reduced survival. Conversely, upregulation of hCD39 
by somatic gene transfer or administration of soluble NTPDases has major benefits in 
inflammation. We have previously shown its advantages with hCD39 being expressed on 
NICC that were transplanted into baboons where it had significant benefits in preventing 
IBMIR and inflammation [37].
There is now clearly abundant protection against hypoxia by the expression or over-
expression of hHO-1, HA-hHO-1, hA20, XIAP, INS-XIAP and genetic manipulation to 
protect against inflammation targeting by hCD39, INS-CD39, hTM, ASGR1-KO, hEPCR, 
hTFPI, and INS-TFPI [11, 13, 37, 55–58]. The use of such systems shows great advances 
and promise for the potential of the CRISPR/Cas9 system in making further genetic modi-
fications in various donor pigs in the pursuit of the ultimate pig for xenotransplantation, 
not just for protection against hypoxia when undergoing islet cell xenotransplantation 
[59].
2.4. Overcoming the innate immune responses by genetic modification
Underpinning the overt innate inflammatory response to pig grafts is an overwhelming pro-
duction of cytokines that includes IL-6 [60]. Along with this immediate cytokine response, 
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direct antigen presentation and complement upregulation also occur. Added together this 
formative assault targets the donor graft once revascularization occurs. Obviously only a 
targeted approach to prevent this cascade of events from occurring can be undertaken by 
direct targeting of antigen reduction and direct complement regulation on the human-anti-
porcine complement dependent cytotoxic responses. A number of approaches have been 
undertaken of late to target this by producing genetically modified animals created using 
CRISPR/Cas9-directed mutation and human transgene delivery. Pigs doubly deficient in 
GGTA1 and CMAH genes have been produced and have been compared to pigs of the 
same background that expressed a human complement regulatory protein (hCRP). A third 
transgenic pig type has also been made deficient in GGTA1, CMAH and B4GalNT2 gene 
expression. Cells from these animals were subjected to measures of human antibody bind-
ing and antibody-mediated complement-dependent cytotoxicity by flow cytometry. Human 
IgG and IgM antibody binding was unchanged between the double knockout and the trans-
genic hCRP double knockout pig. IgG and IgM binding was reduced by 49.1 and 43.2% 
respectively by silencing the B4GalNT2 gene. Compared to the double knockout, human 
anti-porcine cytotoxicity was reduced by 8% with the addition of a hCRP (p = 0.032); It was 
reduced by 21% with silencing the B4GalNT2 gene (p = 0.012). Quite clearly selecting such 
genes to target effectively mediates human antibody-mediated complement dependent 
cytoxicity [22].
Although at first they were not thought to be involved at the time of revascularization, natural 
killer (NK) cells appear to also play a role in xenograft rejection. As such a number of groups 
have targeted HLA-G and HLA-E in an attempt to provide inhibitory receptors of human NK 
cells or macrophages with some effect. Weiss et al. have produced HLA-E/human beta2-micro-
globulin transgenic pigs that provided a small degree of protection against xenogeneic human 
anti-pig natural killer cell cytotoxicity [61]. Maeda et al. demonstrated that by transfecting swine 
endothelial cells to express HLA-E and also HLA-G they significantly suppressed the produc-
tion of pro-inflammatory cytokines from the inflammatory macrophages, which is seen to be an 
important target to help advance islet xenotransplantation [62]. With genetically modified pigs 
that have one or more of the cellular immune response inhibitors already produced for xeno-
transplantation as described above including; hTRAIL, HLA-e/β2 m, pCTLA4-Ig, INS-pCTLA4-
Ig, LEA29Y, hFasL, shTNFRI-Fc and CIITA-DN [11, 13, 60–62]. There would appear to be few 
other variable minor receptors to target, but with the major ones already targeted we are now 
more than readily able to move toward the clinic in regards to suppression of such responses.
2.5. Overcoming T cell responses by genetic modification
Ultimately overcoming the initial immediate barriers is of greatest need but following this 
we still have to provide a defense against the human T cells that recognize the pig MHC 
molecules (SLA). It appears that their response to pig tissue is greater than an allo-immune 
response as seen by the rapid infiltration of islet grafts in the loop model systems even within 
an hour following contact with human blood [7, 63, 64]. We have used standard clinically 
used immunosuppressive therapy in a pig to baboon islet transplant model and seen that the 
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grafts are more rapidly targeted and are eventually rejected by immune mechanisms within 
a month post transplantation [65]. Thus we require much heavier and directed immunosup-
pressive modalities to be able to prolong xenograft survival without causing untoward toxic-
ity to the recipient [65].
As outlined previously, xenografts can become infiltrated with NK cells which are recruited 
by the innate inflammatory response but they can also be stimulated and recruited by upreg-
ulation of CD4+ and CD8+ T cells and macrophages. CD4+ T cells are the predominant cell 
type involved in xenograft rejection with activated CD4+ T cells infiltrating the rejecting pig 
xenograft resulting in IFNγ-mediated activation and infiltration of macrophages and NK cells 
[66–68]. Macrophages participate in recruitment of effector T cells as well as antigen pre-
sentation and cytokine production. Proinflammatory cytokines produced by macrophages, 
including TNFα and IL-6, upregulate tissue factor and can promote both inflammation and 
activation of coagulation [60].
We have seen in a number of studies that conventional doses of common immunosuppres-
sive drugs such as cyclosporine, tacrolimus and glucocorticoids are not effective. However, 
some studies using extremely toxic and non-clinically applicable immunosuppression have 
shown extended graft preservation but lead to an unacceptably high susceptibility to seri-
ous infections in baboons [69]. We have seen some inroads to the success of long-term graft 
survival using the more novel and targeted immunosuppressive agents such as anti-CD154 
Ab treatment in pig islet transplants into monkeys [70]. Using a modified Anti-CD154 based 
immunosuppressive regimen and islets from genetically engineered pigs on an α1, 3-galac-
tosyltransferase gene-knockout background with ubiquitous expression of human CD46 
(GTKO/CD46 pigs), and additional islet beta cell-specific expression of human tissue fac-
tor pathway inhibitor (hTFPI) and/or human CD39 and/or porcine CTLA4-lg, islets were 
intraportally transplanted into diabetic cynomolgus monkeys demonstrating reduced islet 
destruction in the first hours after transplantation. Despite encouraging effects on early islet 
loss, these multi-transgenic islet grafts did not demonstrate consistency in regard to long-
term success, with only two of five demonstrating function beyond five months [71].
Despite several issues being raised with the potential thrombogenic side effects of anti-CD154, 
Cooper’s group have recently published its safe and efficacious use in pig islet transplants in 
monkeys showing no apparent side effects in an extended series of fourteen animals over 
many months in which they describe the extended treatment of their monkeys with the anti-
CD154 and then undertook a critical and extensive analysis of the animals tissues by micros-
copy looking for any microthrombotic or thromboembolic complications [70]. There are also 
further studies utilizing a blocking antibody against CD40 (the receptor for CD154), which is 
showing even more promise for pig heart, and kidney transplants in baboons with no throm-
boembolic complications [72, 73].
Specific targeting of an immunosuppressive factor to be genetically engineered into islets 
could be in place of systemic delivery or if the agent was not suitable for repeated systemic 
treatment. A perfect candidate would appear to be costimulation blockade using anti-CD154 
whose questioned thromboembolic effects would be negated by its local production at the 
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site of the islet. We have also shown suitability of another novel and very effective agent anti-
CD2 whose systemic T cell depletion might be undesirable long term, but if produced locally 
would not affect the majority of the body’s T cells. We have clearly shown it to be efficacious 
in a humanized severe combined immunodeficiency (huSCID) model using transduced NICC 
secreting anti-CD2 to prevent graft rejection [74]. Novel targeting by agents such as anti-CD2 
would appear a very definitive route to take, as CD2 it is expressed on all T cells and sub-
sets of NK cells and unlike most other T cell specific targets; it is expressed more highly on 
memory T cells [75].
If we are to provide comprehensive coverage of all avenues of protection we can also theoreti-
cally target the genetic reduction of the expression of MHC. In fact this has been undertaken 
in a pig-to-baboon artery patch model. Pig arteries expressing a dominant-negative MHC II 
transactivator gene to reduce levels of MHC II (including on endothelial cells) had a modest 
effect. Targeted disruption of MHC I genes in pigs by utilizing CRISPR/Cas9 has also been 
achieved [19] providing an avenue forward for incorporation with the other already demon-
strated to be effective transgenic manipulations to move porcine islet xenotransplantation to 
the clinic.
2.6. Final remarks
There appear very few remaining barriers to be overcome before xenotransplantation can move 
to the clinic. The recent advent of the cutting-edge molecular tools such as ZFNs, TALENs, 
and the CRISPR/Cas9 system have all significantly increased efficiency and precision of the 
production of genetically modified pigs for xenotransplantation [59]. There are a number of 
proof of concept studies already demonstrating long-term islet xenograft survival due to vari-
ous [23, 48, 76], genetic modifications to protect against HAR and IBMIR being mitigated by 
genetically disrupting the α1,3-galactosyltransferase gene and other targeted approaches to 
reduce xenogenicity by targeting GLA, HT, hGnT-III, GT-KO, CMAH, (Neu5Gc)-KO, class 
I MHC-KO, iGb3s-KO, β4GalNT2-KO [11, 13, 17, 22, 23, 37, 40–42]. These have also been 
combined with the transgenic expression of complement regulators hCD59, hCD55/hDAF, 
and hCD46 [11]. There is also abundant protection against hypoxia by the expression or over-
expression of hHO-1, HA-hHO-1, hA20, XIAP, INS-XIAP [11, 13] and genetic manipulation 
to protect against inflammation targeting by hCD39, INS-CD39, hTM, ASGR1-KO, hEPCR, 
hTFPI, and INS-TFPI [11, 13, 37, 55–58].
It would appear the way is clearly open for moving to the clinic since the only remaining bar-
rier, the adaptive immune response, can also be surpassed by the use of new systemic immuno-
suppressive therapies including a combination of local suppression by genetically modifying 
islets to be resistant to cellular rejection. We also have genetically modified pigs that have one 
or more of the cellular immune response inhibitors already produced for xenotransplantation 
including hTRAIL, HLA-e/β2 m, pCTLA4-Ig, INS-pCTLA4-Ig, LEA29Y, hFasL, shTNFRI-Fc 
and CIITA-DN [11, 13, 60–62, 71–75]. All that it would appear to be able to move to the clinic 
is to make the correct selection of the most appropriate combination of genetic manipulations 
to be able to provide the ideal multi-transgenic xenotransplant donor pig.
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CRISPR Clustered regularly interspaced short palindromic repeats
CRISPR/Cas9 CRISPR-associated (Cas)
CMAH Cytidine monophospho-N-acetylneuraminic acid hydroxylase
CK7 Cytokeratin 7
αGal Galactose α1-3 galactose
GTKO Gal Transferase Knockout
GMS Glucose Management System
hCRP Human complement regulatory protein
HFH Human factor H
hHO-1 Human heme oxygenase-1
hCD39 Human CD39
EPCR Human endothelial protein C receptor
HFH Human factor H
huSCID Humanized severe combined immunodeficiency
HAR Hyperacute rejection




LMWD Low molecular weight dextran
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MnSOD Manganese superoxide dismutase
NK Natural killer cells
NICC Neonatal islet cell clusters
NHP Non-human primate
NTPDase Nucleoside triphosphate diphosphohydrolase
PFC Perfluorochemical
PAECs Porcine aortic endothelial cells
SPK Simultaneous pancreas and kidney
T1D Type-1-diabetes
TFPI Tissue factor pathway inhibitor
TALENs Transcription activator-like effector nucleases
TLM Two-layer method
GalT KO or GTKO Xenoantigen αGal
XIAP X-linked inhibitor of apoptosis
ZFNs Zinc finger nucleases
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